These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22145525)

  • 41. Law & psychiatry: SSRIs, suicide, and liability for failure to warn of medication risks.
    Appelbaum PS
    Psychiatr Serv; 2011 Apr; 62(4):347-9. PubMed ID: 21459983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 43. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 44. The FDA, preemption, and public safety.
    Gostin LO
    Hastings Cent Rep; 2011; 41(5):11-2. PubMed ID: 21980892
    [No Abstract]   [Full Text] [Related]  

  • 45. Medical device labeling and advertising: an overview.
    Basile EM; Armentrout E; Reeves KN
    Food Drug Law J; 1999; 54(4):519-33. PubMed ID: 11824451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 47. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 48. Warning signs.
    Nature; 2008 Mar; 452(7185):254. PubMed ID: 18354433
    [No Abstract]   [Full Text] [Related]  

  • 49. TRICARE; off-label uses of devices; partial list of examples of unproven drugs, devices, medical treatments or procedures. Final rule.
    Office of the Secretary, Department of Defense (DoD)
    Fed Regist; 2012 Jun; 77(124):38177-8. PubMed ID: 22737762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 52. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 53. Premarket approval and federal preemption of product liability claims in the wake of Medtronic, Inc. v. Lohr.
    Jarcho DG
    Food Drug Law J; 1996; 51(4):613-8. PubMed ID: 11797730
    [No Abstract]   [Full Text] [Related]  

  • 54. Post-decision diagnosis: medical device preemption alive and mostly well after Medtronic, Inc. v. Lohr.
    Sayler SW; Thomas SM
    Ann Health Law; 1997; 6():185-208. PubMed ID: 10184786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Who is now responsible for discovering and warning about adverse effects of generic drugs?
    Kesselheim AS; Green MD; Avorn J
    JAMA; 2013 Sep; 310(10):1023-4. PubMed ID: 23922000
    [No Abstract]   [Full Text] [Related]  

  • 56. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The "natural" aversion: the FDA's reluctance to define a leading food-industry marketing claim, and the pressing need for a workable rule.
    Farris AL
    Food Drug Law J; 2010; 65(2):403-24, iv. PubMed ID: 24475548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical device preemption after Medtronic, Inc. v. Lohr.
    Neraas MB
    Food Drug Law J; 1996; 51(4):619-29. PubMed ID: 11797731
    [No Abstract]   [Full Text] [Related]  

  • 59. Administrative "health courts" for medical injury claims: the federal constitutional issues.
    Elliott ED; Narayan SA; Nasmith MS
    J Health Polit Policy Law; 2008 Aug; 33(4):761-98. PubMed ID: 18617674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Public Health and the First Amendment.
    Sharfstein JM
    Milbank Q; 2015 Sep; 93(3):459-62. PubMed ID: 26350923
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.